EE03692B1 - 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid - Google Patents

19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE03692B1
EE03692B1 EE9800219A EE9800219A EE03692B1 EE 03692 B1 EE03692 B1 EE 03692B1 EE 9800219 A EE9800219 A EE 9800219A EE 9800219 A EE9800219 A EE 9800219A EE 03692 B1 EE03692 B1 EE 03692B1
Authority
EE
Estonia
Prior art keywords
pregenene
derivatives
pharmaceutical compositions
compositions containing
progestational action
Prior art date
Application number
EE9800219A
Other languages
English (en)
Estonian (et)
Other versions
EE9800219A (xx
Inventor
Piasco Alain
Lafay Jean
Delansorne R�mi
Paris Jacques
Pascal Jean-Claude
Original Assignee
Laboratoire Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Theramex filed Critical Laboratoire Theramex
Publication of EE9800219A publication Critical patent/EE9800219A/xx
Publication of EE03692B1 publication Critical patent/EE03692B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
EE9800219A 1996-01-22 1997-01-17 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid EE03692B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives
PCT/EP1997/000357 WO1997027210A1 (en) 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives

Publications (2)

Publication Number Publication Date
EE9800219A EE9800219A (xx) 1998-12-15
EE03692B1 true EE03692B1 (et) 2002-04-15

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800219A EE03692B1 (et) 1996-01-22 1997-01-17 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid

Country Status (36)

Country Link
US (1) US6180803B1 (no)
EP (2) EP0785212A1 (no)
JP (2) JP4368945B2 (no)
KR (1) KR100396902B1 (no)
CN (1) CN1187366C (no)
AP (1) AP1176A (no)
AR (1) AR005500A1 (no)
AT (1) ATE184015T1 (no)
BR (1) BR9707064A (no)
CA (1) CA2243504C (no)
CO (1) CO4810230A1 (no)
CZ (1) CZ292047B6 (no)
DE (1) DE69700470T2 (no)
DZ (1) DZ2169A1 (no)
EE (1) EE03692B1 (no)
ES (1) ES2140961T3 (no)
GR (1) GR3031954T3 (no)
HK (1) HK1018216A1 (no)
HU (1) HU221796B1 (no)
ID (1) ID15840A (no)
IL (1) IL125379A (no)
IS (1) IS1902B (no)
JO (1) JO1971B1 (no)
MY (1) MY116845A (no)
NO (1) NO309572B1 (no)
NZ (1) NZ330954A (no)
OA (1) OA10813A (no)
PE (1) PE55998A1 (no)
PL (1) PL185608B1 (no)
RU (1) RU2166509C2 (no)
SI (1) SI0886645T1 (no)
TN (1) TNSN97015A1 (no)
TR (1) TR199801399T2 (no)
TW (1) TW411345B (no)
WO (1) WO1997027210A1 (no)
ZA (1) ZA97521B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
AR028110A1 (es) * 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
KR101288265B1 (ko) 2003-09-03 2013-07-26 미스콘 트레이딩 에스.에이. 자궁 내막증의 치료 방법
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109481392B (zh) * 2015-09-02 2021-12-24 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
CZ292047B6 (cs) 2003-07-16
JP4368945B2 (ja) 2009-11-18
ATE184015T1 (de) 1999-09-15
PL327998A1 (en) 1999-01-04
MY116845A (en) 2004-04-30
AP1176A (en) 2003-06-30
KR19990081895A (ko) 1999-11-15
EP0785212A1 (en) 1997-07-23
EE9800219A (xx) 1998-12-15
NZ330954A (en) 1998-10-28
OA10813A (en) 2003-01-28
PE55998A1 (es) 1998-10-01
CA2243504C (en) 2004-03-30
US6180803B1 (en) 2001-01-30
ZA97521B (en) 1997-08-04
KR100396902B1 (ko) 2004-05-03
IL125379A (en) 2003-05-29
TNSN97015A1 (fr) 2005-03-15
AU708135B2 (en) 1999-07-29
HUP9900684A3 (en) 1999-11-29
AR005500A1 (es) 1999-06-23
ES2140961T3 (es) 2000-03-01
SI0886645T1 (en) 1999-12-31
DE69700470T2 (de) 2000-03-30
TW411345B (en) 2000-11-11
CN1209811A (zh) 1999-03-03
NO309572B1 (no) 2001-02-19
AP9801299A0 (en) 1998-09-30
HK1018216A1 (en) 1999-12-17
CZ230798A3 (cs) 1998-11-11
JO1971B1 (en) 1997-12-15
CO4810230A1 (es) 1999-06-30
HUP9900684A2 (hu) 1999-07-28
GR3031954T3 (en) 2000-03-31
IS1902B (is) 2003-11-20
BR9707064A (pt) 1999-12-28
NO983356L (no) 1998-07-21
DE69700470D1 (de) 1999-10-07
DZ2169A1 (fr) 2002-12-25
HU221796B1 (hu) 2003-01-28
PL185608B1 (pl) 2003-06-30
NO983356D0 (no) 1998-07-21
EP0886645A1 (en) 1998-12-30
JP2000503980A (ja) 2000-04-04
CN1187366C (zh) 2005-02-02
TR199801399T2 (xx) 1998-10-21
IL125379A0 (en) 1999-03-12
EP0886645B1 (en) 1999-09-01
AU1595597A (en) 1997-08-20
CA2243504A1 (en) 1997-07-31
RU2166509C2 (ru) 2001-05-10
ID15840A (id) 1997-08-14
IS4800A (is) 1998-07-21
JP2009167188A (ja) 2009-07-30
WO1997027210A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
EE03692B1 (et) 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE9800028A (et) Iprotroopiumsoolad, neid sisaldavad ravimkompositsioonid ja nende kasutamine
EE9900018A (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
HUP9902455A3 (en) 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
IL125849A (en) Substituted benzenesulfonamide derivatives, their preparation and pharmaceutical compositions comprising them
EE9900546A (et) LH-RH peptiidi analoogid, nende kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
HUP0002272A3 (en) Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use
EE03929B1 (et) Sünteetilised polüsahhariidid, nende valmistamisemeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
HUP9904682A3 (en) Phenyloxazole and -thiazole derivatives, their use and pharmaceutical compositions containing them
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
IL112589A0 (en) Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one derivatives, their preparation and pharmaceutical compositions containing them
EE04348B1 (et) Sahhariidderivaadid, neid sisaldav farmatseutiline kompositsioon ja nende kasutamine
EE200000429A1 (et) Sünteetilised polüsahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP9902668A3 (en) Piperazine derivatives, pharmaceutical compositions containing them and their use
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
HUP9902465A3 (en) New amidinium derivatives, pharmaceutical compositions containing same, and uses thereof
FI973229A (fi) Uusi farmaseuttinen koostumus

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20120117